STING Antagonists as ALS Therapeutics: Drug Repurposing

Molecular Mechanism and Rationale

The cGAS-STING (Cyclic GMP-AMP Synthase - Stimulator of Interferon Genes) pathway represents a critical innate immune sensing mechanism that has emerged as a key driver of neuroinflammation in amyotrophic lateral sclerosis (ALS). The molecular cascade begins with the aberrant cytoplasmic accumulation of mitochondrial DNA (mtDNA), which occurs as a downstream consequence of TDP-43 (TAR DNA-binding protein 43) pathology - a hallmark feature observed in over 95% of ALS cases. TDP-43 aggregation and mislocalization from the nucleus to the cytoplasm disrupts normal mitochondrial homeostasis through multiple mechanisms, including impaired mitochondrial RNA processing, defective mitophagy, and compromised mitochondrial membrane integrity. This mitochondrial dysfunction culminates in the release of normally sequestered mtDNA into the cytoplasm, where it acts as a damage-associated molecular pattern (DAMP).

Molecular Mechanism and Rationale

The cGAS-STING (Cyclic GMP-AMP Synthase - Stimulator of Interferon Genes) pathway represents a critical innate immune sensing mechanism that has emerged as a key driver of neuroinflammation in amyotrophic lateral sclerosis (ALS). The molecular cascade begins with the aberrant cytoplasmic accumulation of mitochondrial DNA (mtDNA), which occurs as a downstream consequence of TDP-43 (TAR DNA-binding protein 43) pathology - a hallmark feature observed in over 95% of ALS cases. TDP-43 aggregation and mislocalization from the nucleus to the cytoplasm disrupts normal mitochondrial homeostasis through multiple mechanisms, including impaired mitochondrial RNA processing, defective mitophagy, and compromised mitochondrial membrane integrity. This mitochondrial dysfunction culminates in the release of normally sequestered mtDNA into the cytoplasm, where it acts as a damage-associated molecular pattern (DAMP).

Cytoplasmic mtDNA is recognized by cGAS (MB21D1), a 522-amino acid cytosolic DNA sensor that belongs to the nucleotidyltransferase family. Upon mtDNA binding to its N-terminal domain, cGAS undergoes a conformational change that activates its C-terminal catalytic domain, leading to the synthesis of the cyclic dinucleotide 2'3'-cyclic GMP-AMP (cGAMP) from ATP and GTP. This second messenger molecule then binds to STING (TMEM173), a 379-amino acid endoplasmic reticulum-resident transmembrane protein that serves as the central signaling hub for innate immune activation. STING exists as a dimer with each monomer containing four transmembrane domains and a large C-terminal domain that harbors the cGAMP-binding pocket.

cGAMP binding induces STING oligomerization and translocation from the ER through the ER-Golgi intermediate compartment (ERGIC) to the Golgi apparatus. This trafficking event is essential for STING activation and involves recruitment of the serine/threonine kinase TBK1 (TANK-binding kinase 1) and the transcription factor IRF3 (Interferon Regulatory Factor 3) to perinuclear puncta. TBK1 phosphorylates STING at serine residues 365 and 366 in the C-terminal tail, creating docking sites for IRF3. Activated TBK1 then phosphorylates IRF3 at serines 396 and 398, promoting IRF3 dimerization and nuclear translocation. Concurrently, STING activation triggers NF-κB signaling through recruitment of IKK (IκB kinase) complex components, leading to IκBα phosphorylation, ubiquitination, and degradation, thereby liberating NF-κB subunits for nuclear translocation.

The dual activation of IRF3 and NF-κB drives transcription of type I interferons (IFN-α and IFN-β) and proinflammatory cytokines including TNF-α, IL-1β, and IL-6. In the context of ALS, this inflammatory response occurs in both motor neurons and surrounding glial cells, creating a neurotoxic microenvironment. Activated microglia and astrocytes further amplify the inflammatory cascade through autocrine and paracrine signaling loops, establishing a self-perpetuating cycle of neuroinflammation that accelerates motor neuron degeneration and disease progression.

Preclinical Evidence

Compelling evidence for the therapeutic potential of STING antagonism in ALS comes from multiple complementary experimental approaches across diverse model systems. In the SOD1-G93A transgenic mouse model, one of the most widely studied ALS models, genetic deletion of STING (Tmem173-/-) resulted in significant neuroprotection with delayed disease onset by 15-20 days, extended survival by 25-35 days, and preservation of motor function as measured by rotarod performance and grip strength testing. Histological analysis revealed 40-50% reduction in motor neuron loss in the lumbar spinal cord and decreased glial activation markers including CD68+ microglia and GFAP+ reactive astrocytes.

The TDP-43-A315T transgenic mouse model, which more closely recapitulates human ALS pathology, demonstrated even more striking benefits from STING inhibition. Treatment with the selective STING antagonist H-151 (2-amino-6-[2-(phosphonooxy)ethoxy]-9H-purin-9-yl]methoxy}phosphonic acid) at 5 mg/kg daily via intraperitoneal injection beginning at symptom onset resulted in 35-40% improvement in survival and significant preservation of neuromuscular junction integrity. Quantitative PCR analysis of spinal cord tissue showed 60-70% reduction in interferon-stimulated gene expression, including Ifit1, Isg15, and Mx1, confirming effective pathway inhibition.

C. elegans models expressing human TDP-43 in motor neurons have provided mechanistic insights into the upstream triggers of cGAS-STING activation. These studies demonstrated that TDP-43-mediated mitochondrial dysfunction precedes cGAS-STING activation by 24-48 hours, supporting the temporal sequence of events in the proposed mechanism. Treatment with STING pathway inhibitors rescued motor function defects by 55-65% as measured by thrashing assays and reversed the shortened lifespan phenotype.

In vitro studies using iPSC-derived motor neurons from ALS patients have validated the translational relevance of these findings. Motor neurons harboring C9orf72 hexanucleotide repeat expansions, SOD1 mutations, or TDP-43 mutations all exhibited elevated cGAS-STING pathway activation compared to control lines. Treatment with the STING antagonist SN-011 (4-{[4-amino-6-(4-chlorophenyl)-1,3,5-triazin-2-yl]amino}benzenesulfonamide) at concentrations of 1-10 μM reduced inflammatory cytokine secretion by 70-80% and improved survival under oxidative stress conditions by 45-55%. Single-cell RNA sequencing revealed that STING inhibition reversed disease-associated transcriptional signatures and restored expression of genes involved in axonal transport and synaptic function.

Primary spinal cord cultures from neonatal rats treated with TDP-43 aggregates showed robust cGAS-STING activation within 6-12 hours, accompanied by motor neuron death that was prevented by pretreatment with Compound 18 (N-{4-[6-(4-trifluoromethylphenyl)-1H-imidazo[4,5-b]pyrazin-2-yl]phenyl}acetamide). This protective effect was dose-dependent with an EC50 of approximately 2.8 μM and was maintained for up to 96 hours post-treatment.

Therapeutic Strategy and Delivery

The therapeutic approach leverages existing small molecule STING antagonists that were originally developed for autoinflammatory conditions but possess favorable pharmacological properties for neurological applications. The lead compound H-151 is a direct competitive inhibitor that binds to the cGAMP-binding pocket of STING with a Ki of 38 nM and demonstrates 100-fold selectivity over other cyclic dinucleotide-binding proteins. Pharmacokinetic studies in rodents reveal favorable CNS penetration with a brain-to-plasma ratio of 0.7-0.9 following systemic administration, attributed to its moderate lipophilicity (LogP = 2.1) and low efflux ratio at the blood-brain barrier.

SN-011 represents a next-generation STING antagonist with improved potency (Ki = 8.5 nM) and enhanced CNS penetration (brain-to-plasma ratio = 1.2-1.4). The compound exhibits allosteric inhibition, binding to a site distinct from the cGAMP pocket and inducing conformational changes that prevent STING activation. This mechanism provides theoretical advantages including reduced competition with endogenous cGAMP levels and potential for biased signaling that selectively blocks pathological while preserving physiological STING functions.

For clinical translation, an oral formulation strategy is preferred given the chronic nature of ALS and need for long-term administration. Compound 18 has been successfully formulated as immediate-release tablets with excellent bioavailability (F = 85-92% in humans) and a favorable half-life of 8-12 hours supporting twice-daily dosing. The proposed dosing regimen begins with 50 mg BID for the first week, escalating to 100 mg BID based on tolerability, with a maximum dose of 200 mg BID. Dose adjustments may be necessary in patients with hepatic impairment, as hepatic metabolism via CYP3A4 represents the primary clearance mechanism.

Alternative delivery approaches under investigation include intrathecal administration for direct CNS targeting and nanoparticle formulations for enhanced neural uptake. Lipid nanoparticles encapsulating STING antagonists have shown 3-5 fold increased brain accumulation compared to free drug, with preferential uptake by activated microglia expressing scavenger receptors. This targeted delivery approach could potentially reduce systemic exposure and associated immunosuppressive risks while maximizing therapeutic benefit in the CNS compartment.

Evidence for Disease Modification

The distinction between symptomatic treatment and disease modification in ALS therapeutics is critical for regulatory approval and clinical utility. Multiple lines of evidence support that STING antagonism provides genuine disease-modifying effects rather than merely symptomatic relief. Biomarker studies in preclinical models demonstrate that STING inhibition reduces levels of neurofilament light chain (NfL) in cerebrospinal fluid by 45-60%, indicating decreased neuroaxonal damage. This reduction correlates with preservation of motor neuron counts in histological analyses and occurs independently of any acute effects on motor function.

Advanced MRI techniques including diffusion tensor imaging (DTI) and magnetic resonance spectroscopy (MRS) provide additional evidence for neuroprotection. In SOD1-G93A mice treated with H-151, DTI measurements showed preservation of white matter integrity in the corticospinal tract, with fractional anisotropy values maintained at 75-80% of control levels compared to 45-50% in vehicle-treated animals. MRS detected higher N-acetylaspartate (NAA) to creatine ratios in the motor cortex of treated animals (0.85 ± 0.08 vs. 0.62 ± 0.05), indicating preserved neuronal viability.

Functional outcome measures provide complementary evidence for disease modification. Electrophysiological studies using compound muscle action potential (CMAP) recordings demonstrate that STING antagonist treatment preserves neuromuscular transmission with 60-70% higher amplitudes in treated vs. untreated ALS model mice at advanced disease stages. Motor unit number estimation (MUNE) techniques show 40-50% greater preservation of functional motor units, indicating that the therapeutic effect stems from preventing motor neuron death rather than enhancing residual motor function.

Transcriptomic analyses reveal that STING inhibition reverses disease-associated gene expression signatures, with particular normalization of genes involved in protein homeostasis, mitochondrial function, and axonal transport. Single-nucleus RNA sequencing of spinal cord tissue identifies preservation of motor neuron molecular identity markers including Chat, Isl1, and Mnx1, which are typically downregulated during ALS progression. These molecular signatures of neuroprotection precede and predict functional benefits, supporting a disease-modifying mechanism of action.

Longitudinal studies tracking disease progression rates provide the most compelling evidence for disease modification. In the TDP-43-A315T model, STING antagonist treatment reduces the rate of decline in motor function by 55-65% as measured by slope analysis of rotarod performance over time. This effect on disease progression kinetics, rather than absolute performance levels, indicates interference with underlying pathological processes rather than temporary functional enhancement.

Clinical Translation Considerations

Patient selection strategies for clinical trials must balance the need for homogeneous populations with the reality of ALS heterogeneity. Given the proposed mechanism targeting TDP-43-mediated pathology, trials should initially focus on sporadic ALS patients, who comprise 90-95% of cases and universally exhibit TDP-43 proteinopathy. Biomarker-based stratification using CSF or plasma neurofilament levels could identify patients with active neurodegeneration most likely to benefit from anti-inflammatory intervention. The optimal therapeutic window likely occurs during early disease stages when substantial motor neuron populations remain viable, suggesting enrollment criteria should include symptom duration <18 months and ALSFRS-R scores >30.

Trial design considerations must account for the progressive nature of ALS and regulatory precedents established by previous trials. A randomized, double-blind, placebo-controlled design remains the gold standard, with the ALSFRS-R slope serving as the primary efficacy endpoint. Based on natural history data and effect sizes observed with riluzole, a sample size of 300-400 patients would provide 80% power to detect a 25-30% reduction in disease progression over 12-18 months. Adaptive trial designs incorporating futility analyses and biomarker-driven interim analyses could enhance efficiency and reduce exposure of patients to ineffective treatments.

Safety considerations are informed by existing clinical experience with STING antagonists in autoinflammatory conditions. Phase I studies in healthy volunteers and patients with STING-associated vasculopathy with onset in infancy (SAVI) established a safety profile characterized by dose-dependent increases in infection risk, particularly respiratory tract infections occurring in 15-20% of subjects at therapeutic doses. Comprehensive safety monitoring protocols should include regular assessment of white blood cell counts, immunoglobulin levels, and standardized infection surveillance questionnaires.

The competitive landscape includes established ALS therapies (riluzole, edaravone) and emerging anti-inflammatory approaches targeting different pathways. Potential advantages of STING antagonism include the availability of validated tool compounds, established target engagement biomarkers (interferon gene signatures), and precedent for CNS-penetrant formulations. Regulatory interactions should emphasize the disease-modifying potential supported by multiple biomarkers and the unmet medical need in ALS, where current therapies provide only modest clinical benefits.

Future Directions and Combination Approaches

The modular nature of neuroinflammatory pathways in ALS presents opportunities for rational combination therapies targeting complementary mechanisms. STING antagonism could synergize with inhibitors of upstream triggers such as mitochondrial DNA release or downstream effectors including specific cytokine receptors. Combination with mitochondrial-targeted antioxidants like MitoQ or SS-31 might address both the cause (mitochondrial dysfunction) and consequence (inflammatory activation) of TDP-43 pathology, potentially providing additive neuroprotective effects.

Therapeutic strategies targeting protein aggregation clearance represent logical combination partners given their potential to reduce upstream triggers of cGAS-STING activation. Autophagy enhancers, proteasome activators, or molecular chaperones that reduce TDP-43 aggregate burden could synergize with STING inhibition by addressing root causes while blocking downstream inflammatory amplification. Preclinical studies combining rapamycin (an autophagy inducer) with H-151 have shown preliminary evidence for enhanced efficacy compared to either agent alone.

The intersection between STING signaling and other innate immune pathways offers additional therapeutic targets for combination approaches. Toll-like receptor (TLR) antagonists, NLRP3 inflammasome inhibitors, or complement cascade modulators could provide orthogonal anti-inflammatory effects while preserving essential antimicrobial immunity. Careful consideration of drug-drug interactions and cumulative immunosuppression risks would be essential for safe combination development.

Broader applications to related neurodegenerative diseases are supported by emerging evidence for cGAS-STING pathway activation in Alzheimer's disease, frontotemporal dementia, and other TDP-43 proteinopathies. The pathway's role as a common downstream effector of neuroinflammation suggests that STING antagonists could have utility across multiple neurodegenerative conditions, potentially accelerating development timelines and expanding market opportunities. Biomarker-driven basket trial designs could efficiently evaluate efficacy across multiple indications while identifying optimal patient populations for each disease context.